CD274 and neoplasm: In our study, the cp-PCC drug targeting DHHC3 degradation aimed at reducing PD-L1 not only efficiently degraded the target protein in high-PD-L1-expressing tumor cell lines but also effectively degraded the target protein in ICB-resistant 4T1 cell lines, causing a significant decrease in PD-L1 expression.